Novel drug delivery systems for the management of dry eye
Dry eye disease (DED) is a frequently observed eye complaint, which has recently attracted considerable research interest. Conventional therapy for DED involves the use of artificial tear products, cyclosporin, corticosteroids, mucin secretagogues, antibiotics and nonsteroidal anti-inflammatory drugs.
Highlights
- Many product are used as conventional treatments for dry eye disease (DED).
- Nanotechnology-based drug delivery system are available as novel treatment of DED.
- Progress in the design of nanotechnology-based approaches has been quite remarkable.
- Several nanotherapeutics have approved by FDA, and many others are in clinical trials.
- Many DED drugs, such as mucin secretagogues, are in clinical trials.
In addition, ocular drug delivery systems based on nanotechnology are currently the focus of significant research effort and several nanotherapeutics, such as nanoemulsions, nanosuspensions, microemulsions, liposomes and nanomicelles, are in clinical trials and some have FDA approval as novel treatments for DED. Thus, there has been remarkable progress in the design of nanotechnology-based approaches to overcome the limitations of ophthalmic formulations for the management of anterior eye diseases. This review presents research results on diagnostic methods for DED, current treatment options, and promising pharmaceuticals as future therapeutics, as well as new ocular drug delivery systems.
Download the full review as PDF here Novel drug delivery systems for the management of dry eye
or read it here
Excipients mentioned in this research: Eudragit RS 100, Eudragit RL, PLGA, Lipids, Polysorbate 80, Soluplus, Cyclodextrin
Noriaki Nagai, Hiroko Otake, Novel drug delivery systems for the management of dry eye, Advanced Drug Delivery Reviews, Volume 191, 2022, 114582, ISSN 0169-409X,
https://doi.org/10.1016/j.addr.2022.114582.